Journal
CARDIOLOGY CLINICS
Volume 33, Issue 2, Pages 233-243Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccl.2015.02.004
Keywords
Statins; High intensity statins; Diabetes mellitus; Glucose; Glycemia; Dyslipidemia; Cardiovascular disease; Coronary heart disease
Categories
Funding
- AbbVie
- Amarin
- AstraZeneca
- Trygg Pharmaceuticals
- Aegerion
- Genzyme
- Sanofi
- Merck Pharmaceuticals
Ask authors/readers for more resources
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification. This article summarizes NLA's review of the evidence, expanding it to include recent results, and outlines the clinical recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available